These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26858332)

  • 1. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
    J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.
    Ohgami M; Kaburagi T; Kurosawa A; Doki K; Shiozawa T; Hizawa N; Homma M
    Ther Drug Monit; 2018 Dec; 40(6):699-704. PubMed ID: 29995672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients.
    Veerman GDM; Hussaarts KGAM; Peric R; Oomen-de Hoop E; Landa KD; van der Leest CH; Broerse SD; Rutten HB; Belderbos HNA; Steendam CMJ; Paats MS; Koolen SLW; Dingemans AC; van Gelder T; van Leeuwen RWF; Aerts JGJV; Mathijssen RHJ
    Clin Pharmacokinet; 2021 Jan; 60(1):69-77. PubMed ID: 32557346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
    Veerman GDM; Hurkmans DP; Paats MS; Oomen-de Hoop E; van der Leest CH; van Thiel ERE; Aerts JGJV; van Leeuwen RW; Dingemans AC; Mathijssen RHJ
    Biomed Pharmacother; 2022 Nov; 155():113695. PubMed ID: 36126454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.
    Walravens J; Brouwers J; Spriet I; Tack J; Annaert P; Augustijns P
    Clin Pharmacokinet; 2011 Nov; 50(11):725-34. PubMed ID: 21973269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
    Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
    Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.
    van Doorn L; Heersche N; de Man FM; de Bruijn P; Bijl I; Oomen-de Hoop E; Eskens FALM; van der Gaast A; Mathijssen RHJ; Bins S
    Clin Pharmacol Ther; 2022 Feb; 111(2):455-460. PubMed ID: 34656072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib and acid suppressive agents: is it worth to take a coke?
    Retamero A; Conde-Estévez D
    Ann Oncol; 2017 Jan; 28(1):192-193. PubMed ID: 28177427
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
    Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M
    Lung Cancer; 2016 Sep; 99():94-101. PubMed ID: 27565921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pepsi® or Coke®? Influence of acid on dasatinib absorption.
    Knoebel RW; Larson RA
    J Oncol Pharm Pract; 2018 Mar; 24(2):156-158. PubMed ID: 29284366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
    Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
    Yokota H; Sato K; Okuda Y; Kobayashi H; Takeda M; Asano M; Ito H; Miura M
    Clin Lung Cancer; 2017 Nov; 18(6):e433-e439. PubMed ID: 28579188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression.
    Shimada T; Okano M; Yamada M; Ogawa Y; Ueda A; Nagase K; Sai Y
    Drug Metab Pharmacokinet; 2020 Dec; 35(6):534-538. PubMed ID: 33028492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.
    Lankheet NA; Schaake EE; Burgers SA; van Pel R; Beijnen JH; Huitema AD; Klomp H;
    Clin Lung Cancer; 2015 Jul; 16(4):320-4. PubMed ID: 25682545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug-drug interaction between erlotinib and paracetamol: A potential risk for clinical practice.
    Karbownik A; Szałek E; Sobańska K; Grabowski T; Wolc A; Grześkowiak E
    Eur J Pharm Sci; 2017 May; 102():55-62. PubMed ID: 28232141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
    Todd A; Williamson S; Husband A; Baqir W; Mahony M
    Int J Clin Pharm; 2013 Apr; 35(2):181-4. PubMed ID: 23229875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.